ZIVO vs. AIM, EVAX, APTO, SNTI, PMCB, CRTX, TVGN, BCLI, PLUR, and NKGN
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include AIM ImmunoTech (AIM), Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), Senti Biosciences (SNTI), PharmaCyte Biotech (PMCB), Cortexyme (CRTX), Tevogen Bio (TVGN), Brainstorm Cell Therapeutics (BCLI), Pluri (PLUR), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector.
AIM ImmunoTech (NYSE:AIM) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.
AIM ImmunoTech has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.
ZIVO Bioscience has lower revenue, but higher earnings than AIM ImmunoTech. ZIVO Bioscience is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
In the previous week, AIM ImmunoTech had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for AIM ImmunoTech and 2 mentions for ZIVO Bioscience. AIM ImmunoTech's average media sentiment score of 1.38 beat ZIVO Bioscience's score of -0.23 indicating that ZIVO Bioscience is being referred to more favorably in the news media.
12.0% of AIM ImmunoTech shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by insiders. Comparatively, 13.4% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
ZIVO Bioscience received 43 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 82.35% of users gave AIM ImmunoTech an outperform vote while only 61.11% of users gave ZIVO Bioscience an outperform vote.
ZIVO Bioscience has a net margin of -11,068.75% compared to ZIVO Bioscience's net margin of -14,337.62%. AIM ImmunoTech's return on equity of 0.00% beat ZIVO Bioscience's return on equity.
Summary
ZIVO Bioscience beats AIM ImmunoTech on 9 of the 15 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
